CARE case report guidelines

CARE Checklist of information to include when writing a case report

(cc) BY-NC-ND

Topic	Item	Checklist item description	Reported on Line
Title	**1**	The diagnosis or intervention of primary focus followed by the words "case report"	Lines 1–2
Key Words	**2**	2 to 5 key words that identify diagnoses or interventions in this case report, including "case report"	Line 48
Abstract (no references)	**3a**	Introduction: What is unique about this case and what does it add to the scientific literature?	Lines 30–32
	3b	Main symptoms and/or important clinical findings	Lines 33–36
	3c	The main diagnoses, therapeutic interventions, and outcomes	Lines 37–43
	3d	Conclusion—What is the main "take-away" lesson(s) from this case?	Lines 44–46
Introduction	**4**	One or two paragraphs summarizing why this case is unique (**may include references**)	Lines 73–75
Patient Information	**5a**	De-identified patient specific information.	Lines 78–80
	5b	Primary concerns and symptoms of the patient.	Lines 82–89
	5c	Medical, family, and psycho-social history including relevant genetic information	Lines 78–80; 112–113
	5d	Relevant past interventions with outcomes	Lines 78–80; 91–97
Clinical Findings	**6**	Describe significant physical examination (PE) and important clinical findings.	Lines 82–89
Timeline	**7**	Historical and current information from this episode of care organized as a timeline	Lines 78–127; Table 2; Table 3
Diagnostic Assessment	**8a**	Diagnostic testing (such as PE, laboratory testing, imaging, surveys).	Lines 99–107; 109–117; 119–124; Table 1; Table 2; Table 3-6
	8b	Diagnostic challenges (such as access to testing, financial, or cultural)	Lines 174–176; 383–387
	8c	Diagnosis (including other diagnoses considered)	Lines 99–107
	8d	Prognosis (such as staging in oncology) where applicable	Lines 277–283
Therapeutic Intervention	**9a**	Types of therapeutic intervention (such as pharmacologic, surgical, preventive, self-care)	Lines 84–88; 109–113; 129–133; Figure 2
	9b	Administration of therapeutic intervention (such as dosage, strength, duration)	Lines 84–88; 109–113; 129–133
	9c	Changes in therapeutic intervention (with rationale)	Lines 109–113; 129–133
Follow-up and Outcomes	**10a**	Clinician and patient-assessed outcomes (if available)	Lines 135–145; 147–157
	10b	Important follow-up diagnostic and other test results	Lines 147–157; Table 2; Table 3-6
	10c	Intervention adherence and tolerability (How was this assessed?)	Lines 109–113; 191–201
	10d	Adverse and unanticipated events	Lines 139–141; 155–157
Discussion	**11a**	A scientific discussion of the strengths AND limitations associated with this case report	Lines 383–387
	11b	Discussion of the relevant medical literature **with references**.	Lines 159–387
	11c	The scientific rationale for any conclusions (including assessment of possible causes)	Lines 159–387; 389–391
	11d	The primary "take-away" lessons of this case report (without references) in a one paragraph conclusion	Lines 389–391
Patient Perspective	**12**	The patient should share their perspective in one to two paragraphs on the treatment(s) they received	N/A
Informed Consent	**13**	Did the patient give informed consent? Please provide if requested	**Yes** ☑ **No** ☐